Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen Inc has demonstrated strong financial performance, with a significant 19% year-over-year revenue growth and a notable increase in average selling prices (ASPs) of 9% year-over-year, currently sitting at $441 per test. The company's strategic expansion into additional sales territories, projected to reach 45 by the end of 2025, alongside improvements in commercial leadership, positions it well for continued volume growth. Furthermore, with Q3 revenue increasing by 38% year-over-year and ongoing advancements in reimbursement strategies to support further price increases, Exagen is on track to achieve its long-term ASP target, enhancing a positive outlook for its stock.

Bears say

Exagen Inc's financial outlook appears negative due to a significantly lowered growth projection for 2026, coupled with delayed expectations for positive free cash flow and a decline in peer multiples. These factors have prompted adjustments to the company’s revenue estimates and expectations of more muted gross margin expansion, contributing to a decrease in price targets. Additionally, a notable drop of over 60% in share value following the 3Q25 results has raised concerns among investors regarding the loss of a direct billing account, which accounted for 2% of volume, thereby adversely impacting growth and profitability timelines.

Exagen Inc (XGN) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.